Printer Friendly

Research and Markets: Anticoagulants in Stroke Prevention in Atrial Fibrillation (SPAF): Novel Oral Anticoagulants with Superior Safety Profile will Drive the Market.

DUBLIN -- Research and Markets (http://www.researchandmarkets.com/research/604d83/anticoagulants_in) has announced the addition of GlobalData 's new report "Anticoagulants in Stroke Prevention in Atrial Fibrillation (SPAF): Novel Oral Anticoagulants with Superior Safety Profile will Drive the Market" to their offering.

Anticoagulants in Stroke Prevention in Atrial Fibrillation (SPAF): Novel Oral Anticoagulants with Superior Safety Profile will Drive the Market

Our report, Anticoagulants in Stroke Prevention in Atrial Fibrillation (SPAF): Novel Oral Anticoagulants with Superior Safety Profile will Drive the Market provides key data, information on Anticoagulants in Stroke Prevention in Atrial Fibrillation. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Our team of industry experts.

Scope

Data and information on the most commonly reprocessed market assessment of Stroke Prevention in Atrial Fibrillation and market dynamics

Reasons to buy

* Develop business strategies by understanding the trends and developments that are driving the of Stroke Prevention in Atrial Fibrillation market.

* Design and develop your product development, marketing and sales strategies.

* Develop market-entry and market expansion strategies.

* Identify key players best positioned to take advantage of the market opportunities.

* Make more informed business decisions from the insightful and in-depth analysis of the stroke prevention market and the factors shaping it.

Key Topics Covered:

1 Table of Contents 2 Stroke Prevention in Atrial Fibrillation (SPAF): Introduction

2.1 Overview

2.2 Role of Anticoagulants in SPAF

2.3 Unmet Needs

2.4 Anticoagulants in SPAF: Emerging Landscape

2.5 Anticoagulants in SPAF: Market Dynamics

2.5.1 Market Drivers

2.5.2 Market Restraints

3 Appendix

3.1 Methodology

3.1.1 Coverage

3.1.2 Secondary Research

3.1.3 Primary Research

3.1.4 Expert Panel Validation

3.2 Contact Us

3.3 Disclaimer

For more information visit http://www.researchandmarkets.com/research/604d83/anticoagulants_in
COPYRIGHT 2010 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Dec 16, 2010
Words:398
Previous Article:Research and Markets: Carbon Cap-and-Trade: Implications for Electricity Utility Costs in the US.
Next Article:Research and Markets: External Defibrillators - Global Opportunity Assessment, Competitive Landscape and Market Forecasts to 2016.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters